Stockreport

Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose

Opiant Pharmaceuticals, Inc.  (OPNT) 
Last opiant pharmaceuticals, inc. earnings: 3/4 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.opiant.com/investor-overview
PDF FDA sets PDUFA date of May 22, 2023 SANTA MONICA, Calif., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced tha [Read more]